Skip to main content
. 2019 Apr 7;16(1):70–85. doi: 10.1080/15548627.2019.1598750

Figure 7.

Figure 7.

MIR877-3P targeted and inhibited CTNNBIP1. (a) Potential bind sites of MIR877-3P in CTNNBIP1 3ʹ UTR. (b) Luc-CTNNBIP1 3ʹ UTR-WT or Luc-CTNNBIP1 3ʹ UTR-Mut plasmid was co-transfected with NC or MIR877-3P mimics into HEK293T cells for 24 h. Luciferase activity was determined. (c) After transfection with NC, MIR877-3P inhibitor or mimics overnight, VECs were treated with HG for 48 h. Western blot analysis of CTNNBIP1. (d) VECs were treated with HG for 48 h after transfection with MIR877-3P mimics or co-transfection with MIR877-3P mimics and CA7-4. qPCR analysis of CTNNBIP1 mRNA level. (e,f) VECs were transfected with NC, MIR877-3P mimics or inhibitor for 48 h. (g) VECs were transfected with pcDNA3.1 or CA7-4 (0.1 μg/ml); co-transfected with CA7-4 (0.1 μg/ml) and NC or si-CA7-4 (60 nM) for 48 h. Western blot analysis of CTNNBIP1. (*, p < 0.05; **, p < 0.01; n = 3.).